Differences in ECG- vs. proLonged cardIac MonItor-DeTected Atrial Fibrillation in STROKE Patients
The present study is an investigator-initiated, single-center, retrospective study based on data from the London Ontario Stroke Registry (LOSR), aiming to compare the characteristics and outcomes of ECG-detected and Device-Detected atrial fibrillation in patients with ischemic stroke and transient ischemic attack.
NCT05822791 — Stroke
Status: Active, not recruiting
http://inclinicaltrials.com/stroke/NCT05822791/
The Oslo Study of Visual Impairment After Stroke (StrokeVIS)
Longitudinal, prospective, single-center observational study of visual impairment after stroke. Population: Patients admitted with acute ischemic stroke at the Regional Stroke Unit at Oslo University Hospital who are assessed to not have more serious neurological deficits than to be eligible for a prospective observational study of visual impairment. National Institute of Health Stroke Scale (NIHSS) will be used for screening of the patients eligible for the study with cut off of NIHSS 20. Based on the number of patients admitted to our center to include 120 patients in the StrokeVIS study. The study aims are: 1. To determine the prevalence of visual impairment in stroke patients in the acute phase and after 3 months. 2. To compare visual impairment in those treated with EVT and those not. 3. To determine the sensitivity and specificity of the Vision Screening Assessment (VISA) tool for detection of visual impairment in stroke patients. 4. To assess possible association between brain MRI lesions and visual impairment in stroke patients in the acute phase. 6) To assess any cognitive deficits at 3-month follow-up that could impact visual function. Inclusion criteria: 1. Acute ischemic stroke and NIHSS < 20 2. Age ≥18 years. 3. Written informed consent of the patient or oral informed consent witnessed by a doctor. Exclusion criteria: 1. NIHSS < 20 2. No willingness and ability of the patient to participate in all baseline and follow-up examinations. Duration of study participation: 3 months.
NCT05809973 — Stroke, Acute
Status: Recruiting
http://inclinicaltrials.com/stroke-acute/NCT05809973/
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Ischaemic STROKE (REPO-STROKE IIa)
A combination therapy proposed to be evaluated in this trial, consisting of three already registered compounds with a validated disease mechanism and with known safety profiles, targets key proteins in the dysregulated signal network in stroke, and is expected to synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection. The synergistic mode of action will allow for low doses and is expected to reduce possible side effects while maintaining maximal efficacy
NCT05762146 — Ischemic Stroke, Acute
Status: Recruiting
http://inclinicaltrials.com/ischemic-stroke-acute/NCT05762146/
Thrombolysis Treated by TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Control and Non-inferior Phase Ⅲ Trial, 3T Stroke-Ⅲ
The trial is prospective, randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1 to 0.25mg/kg or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.
NCT05745259 — Acute Ischemic Stroke
Status: Recruiting
http://inclinicaltrials.com/acute-ischemic-stroke/NCT05745259/
Virtually Assisted Home Rehabilitation After Acute Stroke-2 (VAST-rehab2)
The purpose of this study is to assess feasibility of a virtual rehabilitation program in stroke patients and to assess treatment effects, patient goal attainment with self-guided rehabilitation activities, barriers to and facilitators of telerehab, hospital readmission events, and social determinants of health
NCT05737524 — Stroke
Status: Completed
http://inclinicaltrials.com/stroke/NCT05737524/
A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this purpose. RhPro-UK is a specific plasminogen activator. rhPro-UK only acts on occlusive thrombus and has little effect on hemostatic thrombus. In addition, rhPro-UK does not form covalent complexes with protease inhibitors in plasma, so the concentrations of rhpro-UK and protease inhibitors in the blood do not decrease compared with alteplase. Therefore, rhPro-UK therapies have a potential advantage of less systemic bleeding in treated subjects. Data from several previous studies suggest that rhPro-UK is efficacious when used to treat patients with acute myocardial infarction. On April 2, 2011, rhPro-UK injection was approved by the National Medical Products Administration to treat acute myocardial infarction. Since then, rhPro-UK has been widely used to treat myocardial infarction in China. Since 2016, a phase 2 clinical trial was carried to explore the dosing of rhPro-UK in patients with acute ischemic stroke, followed by another study with a sample size of 680 patients to initially validate the efficacy and safety of the proposed dose of 35mg. The results of these studies suggested that rhPro-UK was effective, and there were no safety concerns. To further prove the efficacy and safety of rhPro-UK in patients with acute ischemic stroke, investigators conducted this phase 3 study (PROST-2).
NCT05700591 — Acute Ischemic Stroke
Status: Active, not recruiting
http://inclinicaltrials.com/acute-ischemic-stroke/NCT05700591/
Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package
The aim of this study is to analyze the relationship between the blood biomarker GDF-15 and heart damage after stroke. It is being conducted in France, in the Neurology Department of the Dijon University Hospital (Burgundy). The research is interventional because a biological blood test will be performed, as well as a heart rhythm recording and several cardiac echograms during the hospitalization of the participants and during the follow-up consultation scheduled 4 to 6 months after the stroke. A total of 130 stroke patients will participate in this study. Participation includes 4 visits: - Inclusion visit (within 24 hours of the first stroke symptoms) - visit 1 (within 24 to 72 hours of stroke) - visit 2 (within 48 hours of visit 1) - Visit 3 (approximately 4-6 months post-stroke)
NCT05683873 — Ischemic Stroke
Status: Recruiting
http://inclinicaltrials.com/ischemic-stroke/NCT05683873/
Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors
This study examines the effectiveness of the cardiac rehabilitation program for stroke patients. The study will examine if patients with stroke, who receive cardiac rehabilitation in addition to their standard of care treatments, demonstrate improved recovery of function. It will also examine if these patients have reduced hospital readmission, reduced rate of recurrent stroke, and mortality.
NCT05651945 — Stroke
Status: Recruiting
http://inclinicaltrials.com/stroke/NCT05651945/
Inter-Tester Reliability Of the Cumulated Ambulation Score in Patients With Stroke (InTRO-CAS-Stroke)
CAS is a measurement of basic mobility describing the degree of independence in three activities; getting in and out of bed, sit-to-stand from a chair with armrests, and indoor walking - each assessed on a three-point ordinal scale (0-2), resulting in a total one-day CAS between 0-6 points. Psychometric properties of the CAS has not been investigated i stroke. The design is an inter-tester reliability study.
NCT05601089 — Stroke
Status: Completed
http://inclinicaltrials.com/stroke/NCT05601089/
Telehealth-Enhanced Assessment and Management After Stroke-Blood Pressure
TEAMS-BP is a multicenter, participant-randomized controlled trial designed to compare the effectiveness of Intensive Tailored Telehealth Monitoring (ITTM) versus Intensive Clinic Management (ICM) on Blood Pressure (BP) control and patient activation for BP management following stroke
NCT05539443 — Hypertension Secondary
Status: Completed
http://inclinicaltrials.com/hypertension-secondary/NCT05539443/